113 related articles for article (PubMed ID: 33775050)
21. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance.
Pebody RG; Gay NJ; Hesketh LM; Vyse A; Morgan-Capner P; Brown DW; Litton P; Miller E
Vaccine; 2002 Jan; 20(7-8):1134-40. PubMed ID: 11803074
[TBL] [Abstract][Full Text] [Related]
22. Similar immunogenicity of measles-mumps-rubella (MMR) vaccine administrated at 8 months versus 12 months age in children.
He H; Chen E; Chen H; Wang Z; Li Q; Yan R; Guo J; Zhou Y; Pan J; Xie S
Vaccine; 2014 Jun; 32(31):4001-5. PubMed ID: 24837773
[TBL] [Abstract][Full Text] [Related]
23. Early disappearance of maternal anti-measles, mumps, rubella, and varicella antibodies in Indian infants.
Malshe N; Palkar S; Kulkarni R; Lalwani S; Mishra AC; Arankalle V
Vaccine; 2019 Mar; 37(11):1443-1448. PubMed ID: 30765170
[TBL] [Abstract][Full Text] [Related]
24. Pre-vaccination IgG screening for mumps is the most cost-effectiveness immunization strategy among Health Care Workers.
Coppeta L; Balbi O; Baldi S; Pietroiusti A; Magrini A
Hum Vaccin Immunother; 2019; 15(5):1135-1138. PubMed ID: 30779686
[TBL] [Abstract][Full Text] [Related]
25. Establishing best practices in measles, mumps, and rubella serologic screening for kidney transplant candidates.
Ramakrishna JM; Brumble LM; Larimore KL; Wadei HM; Jarmi T; Libertin CR
Transpl Infect Dis; 2021 Jun; 23(3):e13529. PubMed ID: 33248010
[TBL] [Abstract][Full Text] [Related]
26. Measles, mumps and rubella: control by vaccination.
van Druten JA; de Boo T; Plantinga AD
Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
[TBL] [Abstract][Full Text] [Related]
27. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
Nolan T; McIntyre P; Roberton D; Descamps D
Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
[TBL] [Abstract][Full Text] [Related]
28. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
[TBL] [Abstract][Full Text] [Related]
29. [Economic evaluation on different two-dose-vaccination-strategies related to Measles, Mumps and Rubella Combined Attenuated Live Vaccine].
He HQ; Zhang B; Yan R; Li Q; Fu J; Tang XW; Zhou Y; Deng X; Xie SY
Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Aug; 37(8):1121-6. PubMed ID: 27539345
[TBL] [Abstract][Full Text] [Related]
30. Seroprevalence of measles, mumps & rubella antibodies among 5-10 years old children in north India.
Gupta M; Tripathy JP; Verma M; Singh MP; Kaur R; Ratho RK; Kumar R
Indian J Med Res; 2019 Mar; 149(3):396-403. PubMed ID: 31249206
[TBL] [Abstract][Full Text] [Related]
31. Vaccination Against Measles, Mumps, and Rubella in the Light of Current Epidemic Threats: Unjustified Postponement.
Czajka H; Czajka S; Dyląg KA; Borek E; Kuchar E
Adv Exp Med Biol; 2019; 1153():101-107. PubMed ID: 30758772
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.
Sood A; Mitra M; Joshi HA; Nayak US; Siddaiah P; Babu TR; Mahapatro S; Sanmukhani J; Gupta G; Mittal R; Glueck R
Hum Vaccin Immunother; 2017 Jul; 13(7):1523-1530. PubMed ID: 28362563
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial.
Li Y; Chu SY; Yue C; Wannemuehler K; Xie S; Zhang F; Wang Y; Zhang Y; Ma R; Li Y; Zuo Z; Rodewald L; Xiao Q; Feng Z; Wang H; An Z
Lancet Infect Dis; 2019 Apr; 19(4):402-409. PubMed ID: 30833160
[TBL] [Abstract][Full Text] [Related]
34. [Coverage rate and adverse reactions of National Immunization Program vaccines in children with spinal muscular atrophy: a cross-sectional retrospective cohort study].
Qu YJ; Tian YL; Song F; Wang J; Bai JL; Cao YY; Jin YW; Wang H; Cheng MM
Zhonghua Er Ke Za Zhi; 2020 Apr; 58(4):308-313. PubMed ID: 32234138
[No Abstract] [Full Text] [Related]
35. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
Ceyhan M; Kanra G; Erdem G; Kanra B
Vaccine; 2001 Aug; 19(31):4473-8. PubMed ID: 11483273
[TBL] [Abstract][Full Text] [Related]
36. Prospective Study of Live Attenuated Vaccines for Patients with Nephrotic Syndrome Receiving Immunosuppressive Agents.
Kamei K; Miyairi I; Ishikura K; Ogura M; Shoji K; Funaki T; Ito R; Arai K; Abe J; Kawai T; Onodera M; Ito S
J Pediatr; 2018 May; 196():217-222.e1. PubMed ID: 29499990
[TBL] [Abstract][Full Text] [Related]
37. Previous exposure to measles, mumps, and rubella--but not vaccination during adolescence--correlates to the prevalence of pancreatic and thyroid autoantibodies.
Lindberg B; Ahlfors K; Carlsson A; Ericsson UB; Landin-Olsson M; Lernmark A; Ludvigsson J; Sundkvist G; Ivarsson SA
Pediatrics; 1999 Jul; 104(1):e12. PubMed ID: 10390298
[TBL] [Abstract][Full Text] [Related]
38. Booster immune response in children 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection.
Díaz-Ortega JL; Bennett JV; Castañeda-Desales D; Quintanilla DM; Martínez D; de Castro JF
Vaccine; 2014 Jun; 32(29):3680-6. PubMed ID: 24837512
[TBL] [Abstract][Full Text] [Related]
39. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
McLean HQ; Fiebelkorn AP; Temte JL; Wallace GS;
MMWR Recomm Rep; 2013 Jun; 62(RR-04):1-34. PubMed ID: 23760231
[TBL] [Abstract][Full Text] [Related]
40. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination.
Boulianne N; De Serres G; Ratnam S; Ward BJ; Joly JR; Duval B
Vaccine; 1995 Nov; 13(16):1611-6. PubMed ID: 8578850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
